Monday’s trading session saw a 23.00% rise in the 180 Life Sciences Corp. (NASDAQ: ATNF), a $2.24 price rise from previous market close. The trough of the day 180 Life Sciences stock was $10.02, while the high of the day was $13.05.
According to data from Barchart, the last trading session for the ATNF stock ended at $9.74 with a volume of 43.67 million. At present, there is no current news that could drive the surge in ATNF shares, so recent development could give an indication of its potential.
An online webinar titled, “Controlling Inflammation to Stop Disease” has recently been conducted by 180 Life Sciences.
- At the broadcast, ATNF concluded that ongoing research and clinical trials for anti-tumor necrosis factor antibodies are likely to strengthen the market’s growth and expansion as new anti-TNF uses emerge.
- A recent study by ATNF suggests inflammation plays a role in a number of other illnesses with a high unmet medical need.
- ATNF researchers are conducting ongoing research, and clinical trials are currently taking place with more set to start later this year.
- ATNF stresses that market forecasts may need to be revised significantly higher in the event of success.
Over 30 years, founders of 180 Life Sciences (ATNF) have conducted anti-inflammatory pharmacology research. Being a biotechnology firm, ATNF engages in clinical development of novel treatments for inflammatory diseases using the expertise of world-renowned scientists.
ATNF is currently conducting both preclinical and clinical research of such treatments. The ATNF team leverages the talents and expertise of luminaries from the universities including Oxford, Stanford, and the Hebrew University to pave the way for new research into inflammation that leads to novel treatments.